New oral pharmaceutical compositions and dosing regimens for treating interstitial lung disease with progressive fibrosis
Oral PDE4B inhibitor compositions effectively slow PF-ILD progression with reduced gastrointestinal side effects, addressing the limitations of current treatments by improving therapeutic efficacy and tolerability.
Patent Information
- Application Number
- JP2024531320
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-06-08
- Filing Date
- 2022-12-08
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2042-12-08
AI Technical Summary
Current treatments for progressive fibrotic interstitial lung diseases (PF-ILD), such as idiopathic pulmonary fibrosis (IPF), are unable to halt disease progression and are associated with significant gastrointestinal side effects, limiting their efficacy and patient compliance.
Development of oral pharmaceutical compositions containing a PDE4B inhibitor of formula III, administered at doses of 18 mg or 9 mg twice daily, either alone or in combination with standard of care treatments like nintedanib or pirfenidone, to treat PF-ILD, particularly IPF, with a focus on improving therapeutic efficacy and tolerability.
The PDE4B inhibitor demonstrates significant slowing of lung function decline in PF-ILD patients, with reduced gastrointestinal side effects, particularly when combined with pirfenidone, enhancing treatment compliance and safety.
Smart Images

Figure 2024543161000001_ABST
Abstract
Description
[Technical field]
[0001] 1.1 Phosphodiesterases and their role in fibrosis Phosphodiesterases (PDEs) mediate the hydrolysis of the second messengers cyclic adenosine monophosphate (cAMP) or cyclic guanosine monophosphate. PDEs are encoded by 11 gene superfamilies that contain multiple genes and also produce alternative mRNA-splicing variants resulting in approximately 100 PDE isoforms (encoding subtypes A, B, C, etc.). PDE4 has previously been implicated in the control of inflammation and the regulation of immune-competent cells, and the three currently available selective PDE4 inhibitors support a beneficial role for PDE4 inhibitors in inflammatory and / or autoimmune diseases (Sakkas et al., 2017, Curr. Med. Chem. 24, 3054-3067; Li et al., 2018, Front. Pharmacol. 9, 1048). Oral roflumilast (Daliresp®, Daxas®), a first-in-class PDE4 inhibitor, was approved by the US Food and Drug Administration in 2011 to reduce the risk of COPD exacerbations in patients with severe COPD and a history of exacerbations associated with chronic bronchitis (US Food & Drug Administration, 2013, DALIRESP® (roflumilast)). Another compound, oral apremilast (Otezla®), was approved in 2014 for the treatment of psoriatic arthritis and plaque psoriasis (US Food & Drug Administration, 2017, OTEZLA® (apremilast)). A third PDE4 inhibitor, crisaborole (Eucrisa®), was approved in 2016 for the topical treatment of mild to moderate atopic dermatitis (US Food & Drug Administration, 2016, EUCRISA TMAmong these, none show any preferential enzyme inhibition among the four PDE4 subtypes A to D.
[0002] The general anti-inflammatory potential of PDE4 inhibition is well established, as exemplified by roflumilast (Hatzelmann et al., 2010, Pulm. Pharmacol. Ther. 23, 235-256), and the use of PDE4 inhibitors in various inflammatory and immune-mediated diseases has been widely investigated (Sakkas et al., 2017, Curr. Med. Chem. 24, 3054-3067; Li et al., 2018, Front. Pharmacol. 9, 1048). However, over the last decade, it has become increasingly clear that PDE4 may also play a key role in fibrosis, based on animal studies evaluating the functional role of PDE4 inhibitors in fibroblasts, and on in vitro experiments. Attenuation of pulmonary fibrosis by PDE4 inhibitors has been demonstrated under a variety of experimental conditions, most extensively in bleomycin-induced fibrosis in rodents. In a rat model, rolipram was shown to inhibit fibrosis scores, hydroxyproline content, and serum tumor necrosis factor-α (TNF-α) (Pan et al., 2009, Respirology 14, 975-982). In this initial study, the PDE4 inhibitor was administered from the start of the bleomycin challenge, so it was not clear whether rolipram was primarily active by inhibiting early inflammation or secondary fibrosis. However, a second early study in mice and rats showed that oral roflumilast was active in both preventive and therapeutic protocols in a dose-dependent manner (Cortijo et al., 2009, Br. J. Pharmacol. 156, 534-544). In lung extracts, roflumilast inhibited histologically assessed fibrosis, hydroxyproline content, and mRNA expression of TNF-α, transforming growth factor-β (TGF-β), connective tissue growth factor (CTGF), α1 collagen, endothelin-1, and mucin 5ac. In bronchoalveolar lavage fluid (BALF), levels of TNF-α, interleukin (IL)-13, TGF-β, and mucin 5ac, formation of lipid hydroperoxides, and influx of inflammatory cells (e.g., neutrophils and macrophages) were inhibited.Besides fibrosis, right ventricular hypertrophy and vascular remodeling (pulmonary artery) were favorably affected by roflumilast. The same group later demonstrated that the metabolome associated with pulmonary fibrosis in bleomycin mice was also modulated by roflumilast. Levels of the amino acids (AA) glycine and proline involved in collagen formation / structure were decreased by roflumilast, while pulmonary glutathione and plasma tetrahydrobiopterin were increased, suggesting a change in oxidative balance by roflumilast (Milara et al., 2015, PLoS One 10, e0133453). Cilomilast, another PDE4 inhibitor, has been shown to inhibit late-stage pulmonary fibrosis and reduce collagen content in bleomycin mice, but tended to have no effect on TGF-β1 and collagen type (Col) 1A1 expression (Udalov et al., 2010, BMC Pulm. Med. 10, 26).
[0003] The amelioration of pulmonary fibrosis by PDE4 inhibition was not limited to the bleomycin model. In a mouse model of pulmonary fibrosis targeting type II alveolar epithelial cells in transgenic mice expressing the diphtheria toxin receptor under the control of the mouse surfactant protein C promoter, roflumilast reduced lung hydroxyproline content and mRNA expression of TNF-α, fibronectin (FN) and CTGF (Sisson et al., 2018, Physiol. Rep. 6, e13753). Interestingly, roflumilast was active both in preventive and therapeutic regimens, and under the latter conditions appeared therapeutically equipotent with pirfenidone and nintedanib. Furthermore, in a mouse model of chronic graft-versus-host disease, pulmonary fibrosis was attenuated by oral roflumilast (Kim et al., 2016, Exp. Hematol. 44, 332-341.e334). Roflumilast inhibited fibrosis, collagen deposition, hydroxyproline and TGF-β1 content, cell infiltration, and IL-6 and IL-1β mRNA expression. Furthermore, in BALF inflammatory cells (macrophages, lymphocytes, neutrophils, and eosinophils), IL-6, IL-1β, and monocyte chemoattractant protein-1 mRNA expression was inhibited by roflumilast. In a rabbit tuberculosis model, lung injury and fibrosis were shown to be inhibited by two PDE4 inhibitors from Celgene, CC-3052 (Subbian et al., 2011, Am. J. Pathol. 179, 289-301) and CC-11050 (Subbian et al., 2016, EBioMedicine 4, 104-114). PDE4 inhibition improved antibiotic therapy and pulmonary fibrosis by favorably affecting collagen deposition and mRNA expression of various matrix metalloproteinases, including metalloproteinase 12.
[0004] Besides the lung, the beneficial effect of PDE4 inhibition on fibrosis has been demonstrated in several other organs, including the skin, liver, kidney and colon. For example, in various preclinical mouse models of SSc, skin fibrosis was induced by bleomycin or topoisomerase I, and chronic graft-versus-host disease was inhibited by rolipram and apremilast (Maier et al., 2017, Ann. Rheum. Dis. 76, 1133-1141). This group found no direct inhibitory effect of PDE4 inhibition on the release of profibrotic cytokines (IL-6, IL-13, TGF-β1 / β2) in fibroblasts from patients with SSc and in M2 macrophages purified from the peripheral blood of these patients, which may be due to the lack of an exogenous cAMP trigger under the experimental conditions used. In a model of obstructive nephropathy induced by unilateral ureteral obstruction in mice, rolipram was shown to inhibit renal interstitial fibrosis (Ding et al., 2017, Antioxid. Redox Signal. 29, 637-652). In primary mouse renal tubular epithelial cells in vitro, TGF-β upregulated PDE4A / B, and rolipram inhibited TGF-β-induced damage, FN expression, and impaired mitochondrial biogenesis. Roflumilast inhibited diethylnitrosamine-induced liver fibrosis, hydroxyproline deposition, and TGF-β1 expression in rats (Essam et al., 2019, Life Sci. 222, 245-254). Similarly, rolipram upregulated PDE4A, B and D and inhibited collagen deposition, α-smooth muscle actin (α-SMA) staining and mRNA expression, as well as TGF-β1 mRNA and TNF-α protein expression in a bile duct ligation-induced liver fibrosis model in rats (Gobejishvili 2019). In hepatic stellate cells in vitro, rolipram inhibited α-SMA and Col1A2 mRNA expression (Gobejishvili et al., 2013, J. Pharmacol. Exp. Ther. 347, 80-90).In colonic tissue, rolipram inhibited collagen and TGF-β1 in a rat model of trinitrobenzenesulfonic acid-induced colitis (Videla et al., 2006, J. Pharmacol. Exp. Ther. 316, 940-945), and apremilast inhibited colonic fibrosis, collagen deposition, and expression of fibrosis-related genes in a mouse model of dextran sulfate sodium-induced ulcerative colitis (Li et al., 2019, Br. J. Pharmacol. 176, 2209-2226). In a mouse cecal scraping model, rolipram inhibited the fibrogenic response, indicating that PDE4 inhibition has the ability to prevent postoperative intraperitoneal adhesions (Eser et al., 2012, Dis. Colon Rectum 55, 345-350). It is assumed that adhesions result from laparotomy with abnormal healing. In support of this assumption, rolipram has been shown to be active in subcutaneous or intraperitoneal polyether-polyurethane sponge implant models in mice by inhibiting collagen and TGF-β1 deposition within the implant (Mendes et al., 2009, Microvasc. Res. 78, 265-271). Thus, the beneficial effect of selective PDE4 inhibition on fibrosis has been demonstrated in various animal models, not only in the lung but also in several other organs on a very broad scale. Although the specific targets of PDE4 inhibitors in fibrotic diseases are largely unknown, it is tempting to speculate that PDE4 inhibitors act indirectly via the inhibition of proinflammatory cells and mediators and / or directly by the inhibition of typical effector cells (fibroblasts, myofibroblasts) that mediate fibrosis.
[0005] Direct regulation of various fibroblast functions by PDE4 inhibitors was demonstrated in fibroblast cell lines of human origin. Kohyama et al. demonstrated the direct effect of PDE4 inhibitors on fibroblasts in vitro (Kohyama et al., 2004, Clin. Immunol. 111, 297-302). In human fetal lung fibroblasts (HFL-1), rolipram and cilomilast inhibited FN-induced chemotaxis and collagen gel contraction. Inhibition of fibroblast functions by prostaglandin E2 (PGE2) was shifted to the left in the presence of PDE4 inhibitors, and inhibition of endogenous PGE2 by indomethacin was less effective (Kohyama et al., 2002, Am. J. Respir. Cell Mol. Biol. 26, 694-701). Inhibition of fibroblast cell line HFL-1 function by cilomilast could be mediated by cytokines such as IL-1β (up-regulating PGE2 and shifting the cilomilast curve to the left) or IL-4 (down-regulating PGE2 and shifting the cilomilast curve to the right). Inhibition of HFL-1 function (FN-stimulated chemotaxis and collagen gel contraction) by rolipram and roflumilast was dependent on cyclooxygenase-2 expression and subsequent PGE2 synthesis (Kohyama et al., 2002, Am. J. Respir. Cell Mol. Biol. 26, 694-701). Furthermore, TGF-β1-stimulated FN release was inhibited by PDE4 inhibitors in parallel with the stimulation of PGE2 release as a positive feedback mechanism (Togo et al., 2009, Am. J. Physiol. Lung Cell Mol. Physiol. 296, L959-L969.).In another human fetal lung fibroblast cell line (GM06114), roflumilast's active metabolite, roflumilast N-oxide, was shown to inhibit TNF-α-stimulated intercellular adhesion molecule-1 and eotaxin release in the presence of PGE2, basic fibroblast growth factor (bFGF) and IL-1β-stimulated proliferation, and TGF-β1-induced α-SMA, CTGF, and FN mRNA expression in the presence of IL-1β (Sabatini et al., 2010, Pulm. Pharmacol. Ther. 23, 283-291). Importantly, IL-1β upregulated the activity of PDE4.
[0006] In normal human lung fibroblasts (NHLF), the effects of PDE4 inhibitors have been described in several publications. It has been shown that TGF-β-induced fibroblast-to-myofibroblast conversion, assessed by α-SMA expression, is inhibited by piclamilast in the presence of PGE2 (Dunkern et al., 2007, Eur. J. Pharmacol. 572, 12-22). In a subsequent paper, the same group demonstrated the inhibition of IL-1β- and bFGF-stimulated fibroblast proliferation by piclamilast, as well as the importance of cyclooxygenase-2 and PGE2 (Selige et al., 2010, J. Cell. Physiol. 223, 317-326). Using siRNA specific for PDE4 subtypes, the involvement of PDE4B and PDE4A in this response, as well as PDE4B and PDE4D in TGF-β-induced α-SMA expression was shown (Selige et al., 2011, J. Cell. Physiol. 226, 1970-1980). The importance of cAMP triggering to regulate fibroblast function by PDE4 inhibition was supported by the inhibition by roflumilast of TGF-β1-induced CTGF mRNA and α-SMA protein expression, as well as of FN in the presence of the long-acting β2-adrenergic agonist indacaterol (Tannheimer et al., 2012, Respir. Res. 13, 28). Furthermore, various other NHLF responses stimulated by bleomycin or 8-epi-PGF2α (collagen synthesis, proliferation, reactive oxygen species and F2-isoprostane formation, NADPH oxidase 4 expression) were inhibited by roflumilast N-oxide (Vecchio et al., 2013, Mediators Inflamm. 2013, 745984).In yet another human lung fibroblast model (WI-38), TGF-β-induced collagen α1, CTGF, and FN mRNA expression in the presence of the adenyl cyclase activator forskolin was inhibited by roflumilast and another PDE4 inhibitor (compound 1) (Sisson et al., 2018, Physiol. Rep. 6, e13753), as well as a dual-selective PDE4 / 5 inhibitor (compound A) (Muraki et al., 2019, Biosci. Biotechnol. Biochem. 83, 1000-1010).
[0007] Thus, many in vitro studies indicate that PDE4 inhibitors can directly inhibit various fibroblast functions, regardless of whether endogenous or exogenous cAMP triggers are available in the test system.The availability of cAMP agonists may be limited under artificial in vitro conditions, but it can be expected that cAMP agonists such as PGE2, adenosine, histamine or adrenaline can be formed in pathological (inflammation, fibrosis) tissue.The importance of PDE4 under such conditions can be further enhanced by the upregulation of PDE4 activity by cytokines, such as IL-1β.
[0008] Another interesting aspect of fibrosis regulation, epithelial-mesenchymal transition, was addressed in vitro in the A549 human alveolar epithelial cell line stimulated with TGF-β1. TGF-β1 stimulated upregulation of PDE4 subtypes (PDE4A and 4D), and rolipram and siRNA inhibited epithelial-mesenchymal transition changes such as FN and collagen mRNA expression, but not α-SMA mRNA (Kolosionek et al., 2009, Mol. Biol. Cell 20, 4751-4765). [Background technology]
[0009] 1.2 Progressive fibrosing interstitial lung disease (PF-ILD) Interstitial lung disease (ILD) comprises a heterogeneous group of lung diseases that affect the interstitium, which are differentiated from obstructive airway diseases, such as asthma or chronic obstructive pulmonary disease (COPD). Prolonged ILD can, but does not always, lead to pulmonary fibrosis. The most extensively studied ILD is idiopathic pulmonary fibrosis (IPF), which is characterized by progressive pulmonary fibrosis. Non-IPF ILDs can include connective tissue disease-associated ILDs, such as those associated with rheumatoid arthritis and other autoimmune diseases, systemic sclerosis-associated ILDs (SSc-ILDs), and polymyositis / dermatomyositis, as well as ILDs associated with chronic sarcoidosis, chronic hypersensitivity pneumonitis, idiopathic nonspecific interstitial pneumonia, and exposure-associated diseases, such as asbestosis and silicosis (Cottin et al, . Eur. Respir. Rev. 28, 180100; Kolb, M., and Vasakova, M. (2019), Respir. Res. 20, 57). Up to 40% of patients with these ILDs can develop a progressive fibrotic phenotype.
[0010] Progressive fibrosing ILD is associated with a high mortality rate, and the median survival after diagnosis in patients with IPF is estimated to be 2-5 years (Raghu, G., Chen, SY, Yeh, WS, Maroni, B., Li, Q., Lee, YC, and Collard, HR (2014). Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11. Lancet Respir. Med. 2, 566-572). The progression of fibrotic ILD is reflected by various parameters including decline in lung function, reduced exercise capacity, deterioration of quality of life, worsening cough and dyspnea, acute exacerbations, and increasing morphological abnormalities (Cottin et al. Eur. Respir. Rev. 28, 180100, 2019; Kolb and Vasakova, 2019, Respir. Res. 20, 57). In patients with IPF, forced vital capacity (FVC) is a well-established predictor of death, and acute exacerbations are associated with a very high mortality rate. Although corticosteroids and / or immunosuppressants may be used off-label to treat progressive fibrotic ILD, the only currently approved treatments that slow disease progression in IPF are nintedanib and pirfenidone (Richeldi et al., 2018, Eur. Respir. Rev. 27, 180074).Nintedanib has been approved in the United States since 2014 (US Food & Drug Administration, 2020, OFEV(R) (nintedanib)) and in Europe and Japan since 2015 (European Medicines Agency, 2021b, OFEV(R) (nintedanib)), whereas pirfenidone has been approved in Japan since 2008, in Europe since 2011 (European Medicines Agency, 2021a, Esbriet (pirfenidone)) and in the United States since 2014 (US Food & Drug Administration, 2019, ESBRIET(R) (pirfenidone)). Lung transplantation is the only therapeutically viable treatment for IPF, and medical demand in IPF and other progressive fibrotic ILDs remains high.
[0011] However, in patients with IPF and mild or moderate impairment of FVC (≥ 50% predicted), the currently approved drugs pirfenidone and nintedanib were only able to reduce the decline in FVC, equivalent to slowing disease progression, but neither was able to halt or even reverse or reverse the symptoms of IPF (Tzouvelekis et al Ther. Clin. Risk Management 2015, 11, 359-370). Nevertheless, both treatment options, with pirfenidone or with nintedanib, show significant beneficial effects in slowing IPF disease progression. The most prominent side effects associated with both nintedanib and pirfenidone are gastrointestinal events, particularly diarrhea, nausea, vomiting, abdominal pain, decreased appetite and weight loss. In cases where gastrointestinal side effects occur, they are usually managed by interrupting treatment, reducing dose, or symptomatic treatment of gastrointestinal side effects (see Mazzei et al, Ther. Adv. Respir. Dis. 2015, Vol. 9 [3], pp. 121-129).
[0012] Due to these "cumulative gastrointestinal side effects" of pirfenidone on the one hand and nintedanib on the other hand, combination treatment of IPF with a combination of pirfenidone and nintedanib is not frequently used. Studies have shown that combination treatment with pirfenidone and nintedanib leads to increased gastrointestinal side effects, specifically diarrhea, nausea, vomiting and epigastric pain (Vancheri et al., nintedanib with Add-on pirfenidone in Idiopathic Pulmonary Fibrosis: Results of the INJOURNEY Trial. Am J Respir Crit Care Med. 2017, Epub ahead of print). As a result, both of the active agents approved to treat IPF thus far, pirfenidone and nintedanib, when administered alone, are unable to stop or cure IPF, but instead can only slow IPF disease progression by a certain percentage (Tzouvelekis et al Ther. Clin. Risk Management 2015, 11, 359-370), and furthermore, both nintedanib and pirfenidone exhibit significant gastrointestinal side effects, which are cumulative when both compounds are combined, there remains a significant medical need for improved methods of treating IPF / PF-ILD, specifically improved therapeutic efficacy (compared to standard of care treatment) combined with acceptable tolerability / safety, specifically with regard to gastrointestinal side effects.
[0013] 1.3 Patent documents In addition to the approved PDE4 inhibitors roflumilast and apremilast, a number of further patent applications have been published describing other PDE4 inhibitors with improved properties: - Pteridines as PDE4-inhibitors in WO2006 / 056607, WO2006 / 058869, WO2006 / 058868 and WO2006 / 058867. - Piperidino-dihydrothienopyrimidines as PDE4-inhibitors in WO2006 / 111549, WO2007 / 118793 and WO2009 / 050242. - WO2009 / 050248 and WO2013 / 026797 use piperidino-dihydrothienopyrimidines as PDE4-inhibitors. Summary of the Invention
[0014] PDE4-inhibitors of formula I [ka] and PDE4-inhibitors of formula II
[0015] [ka] and in particular PDE4 inhibitors of formula III which are the R-enantiomers of the compounds of formula II.
[0016] [ka] are disclosed in WO2013 / 026797. The PDE4-inhibitors of formula I, II and III have been shown to preferentially inhibit the PDE4B subtype. WO2019 / 081235 discloses a combination of nintedanib and a PDE4 inhibitor of formula III that exhibits a superadditive synergistic effect on fibroblast proliferation in an in vitro assay using human lung fibroblasts.
[0017] Thus, neither WO2013 / 026797 nor WO2019 / 081235 disclose oral compositions and / or dosing regimens of PDE4-inhibitors of formula III that combine both good therapeutic efficacy (alone and in combination with the standard of care treatment, which is nintedanib treatment or pirfenidone treatment) and an acceptable tolerability / safety profile in human PF-ILD / IPF-patients, in particular with tolerable gastrointestinal adverse events / side effects. However, only oral compositions and dosing regimens with administration combining both a satisfactory therapeutic efficacy for the treatment of PF-ILD, preferably IPF, on the one hand, and acceptable tolerability / safety on the other hand, will lead to sufficient compliance and thus to an adequate PF-ILD / IPF-treatment for patients. As a result, the object of the present invention is to provide oral compositions and dosing regimens comprising a suitable dose of a PDE4 inhibitor of formula III, which combine both a satisfactory therapeutic efficacy and an acceptable tolerability / safety profile for the treatment of PF-ILD patients, preferably IPF patients, thereby leading to good compliance.
[0018] This problem of the present invention has been solved by the results of a 12-week clinical trial evaluating the efficacy, safety and tolerability of a PDE4 inhibitor of formula III, alone or in combination with standard of care IPF-treatment (with nintedanib or pirfenidone), in IPF patients (phase II), which resulted in new oral pharmaceutical compositions comprising a PDE4 inhibitor of formula III. [ka] In a dose of 18 mg or 9 mg for use in treating PF-ILD patients, preferably for use in treating IPF patients, this oral pharmaceutical composition is administered twice daily (bid) to said PF-ILD patients, or preferably IPF patients. In a preferred embodiment, the PDE4-inhibitor of formula III is administered to PF-ILD patients, preferably IPF patients, at a dose of 18 mg twice daily. 2. Description of the Invention DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0019] In a first aspect, the present invention relates to an oral pharmaceutical composition for use in the treatment of one or more progressive fibrotic interstitial lung diseases (PF-ILDs), comprising a PDE4B-inhibitor of formula III in a dose of 18 mg or 9 mg, [ka]
[0020] This oral pharmaceutical composition is administered to the patient twice daily. In a preferred embodiment, the PDE4-inhibitor of formula III is administered to PF-ILD patients, preferably IPF patients, at a dose of 18 mg twice daily. In a preferred embodiment of the oral pharmaceutical composition referred to above, the one or more progressive fibrotic interstitial lung diseases (PF-ILDs) is idiopathic pulmonary fibrosis (IPF). In a further preferred embodiment of the above mentioned oral pharmaceutical composition, said oral pharmaceutical composition is a film-coated tablet.
[0021] In a further aspect, the invention essentially comprises a PDE4B-inhibitor of formula III at a dose of 9 mg [ka] And, - An oral pharmaceutical composition for use in treating a patient suffering from one or more progressive fibrotic interstitial lung diseases (PF-ILDs), more preferably a patient suffering from diopathic pulmonary fibrosis (IPF), optionally comprising one or more pharmacologic carriers or excipients, the oral pharmaceutical composition being administered to the patient twice daily.
[0022] In a more preferred embodiment, the present invention essentially comprises: A PDE4B-inhibitor of formula III at a dose of 18 mg [ka] And, - an oral pharmaceutical composition for use in the treatment of one or more progressive fibrotic interstitial lung diseases (PF-ILD), more preferably for use in the treatment of idiopathic pulmonary fibrosis (IPF), optionally comprising one or more pharmacokinetic or kinetically acceptable carriers or excipients, This oral pharmaceutical composition is administered to the patient twice daily. Herein, these oral pharmaceutical compositions consist essentially of a PDE4B inhibitor of formula III in a dose of 18 mg or 9 mg, and optionally one or more pharma- ceutically acceptable carriers or excipients, to be administered twice daily, preferably as a film-coated tablet.
[0023] In another preferred embodiment, the present invention comprises: A PDE4B inhibitor of formula III is used as the sole active agent [ka] 9mg dose and - an oral pharmaceutical composition, optionally comprising one or more pharma- ceutical acceptable carriers or excipients, for use in the treatment of patients suffering from one or more progressive fibrotic interstitial lung diseases (PF-ILDs), more preferably patients suffering from idiopathic pulmonary fibrosis (IPF); This oral pharmaceutical composition is administered to the patient twice daily.
[0024] In another preferred embodiment, the present invention comprises: A PDE4B inhibitor of formula III is used as the sole active agent [ka] A dose of 18 mg and - an oral pharmaceutical composition, optionally comprising one or more pharma- ceutical acceptable carriers or excipients, for use in the treatment of patients suffering from one or more progressive fibrotic interstitial lung diseases (PF-ILDs), more preferably patients suffering from idiopathic pulmonary fibrosis (IPF); This oral pharmaceutical composition is administered to the patient twice daily.
[0025] These oral pharmaceutical compositions herein containing a PDE4B inhibitor of formula III as the sole active agent at the above-mentioned doses of 9 mg or 18 mg and optionally containing one or more pharma- ceutically acceptable carriers or excipients are preferably film-coated tablets. In a second aspect, the present invention relates to the use of a PDE4B inhibitor of formula III for the manufacture of an oral pharmaceutical composition for the treatment of patients suffering from progressive fibrotic interstitial lung disease (PF-ILD), consisting essentially of a PDE4B inhibitor of formula III in a dose of 18 mg or 9 mg, and optionally one or more pharma- ceutically acceptable carriers or excipients,
[0026] [ka] The oral pharmaceutical composition should be administered to the patient twice daily.
[0027] In a preferred embodiment of the above mentioned use, the PDE4B-inhibitor of formula III is administered to PF-ILD patients, preferably IPF patients, in a dose of 18 mg twice daily. In a preferred embodiment of the above-mentioned use of a PDE4B inhibitor of formula III for the manufacture of an oral pharmaceutical composition for treating a patient suffering from PF-ILD, consisting essentially of a dose of 18 mg or 9 mg of a PDE4B inhibitor of formula III and, optionally, one or more pharma- ceutically acceptable carriers or excipients, the interstitial lung disease with progressive fibrosis (PF-ILD) is idiopathic pulmonary fibrosis (IPF). In a further preferred embodiment of the above mentioned use of a PDE4B inhibitor of formula III for the manufacture of an oral pharmaceutical composition for treating a patient suffering from PF-ILD, consisting essentially of a PDE4B inhibitor of formula III in a dose of 18 mg or 9 mg and, optionally, one or more pharma- ceutically acceptable carriers or excipients, the oral pharmaceutical composition is a film-coated tablet.
[0028] In a third aspect, the present invention provides a method for producing a pharmaceutical composition comprising the steps of: 18 mg or 9 mg of a PDE4B inhibitor of formula III [ka] A therapeutically effective dose of nintedanib and - an oral pharmaceutical composition for treating a patient suffering from progressive fibrotic interstitial lung disease (PF-ILD), optionally comprising one or more pharma- ceutical acceptable carriers or excipients, This oral pharmaceutical composition is administered to the patient twice daily.
[0029] In a preferred embodiment, the present invention comprises: 18 mg or 9 mg of a PDE4B inhibitor of formula III [ka] and 150mg of nintedanib and - an oral pharmaceutical composition for treating a patient suffering from progressive fibrotic interstitial lung disease (PF-ILD), optionally comprising one or more pharma- ceutical acceptable carriers or excipients, This oral pharmaceutical composition is administered to the patient twice daily.
[0030] In another preferred embodiment, the present invention comprises: 18 mg or 9 mg of a PDE4B inhibitor of formula III [ka] and 100mg of nintedanib and - an oral pharmaceutical composition for treating a patient suffering from progressive fibrotic interstitial lung disease (PF-ILD), optionally comprising one or more pharma- ceutical acceptable carriers or excipients, This oral pharmaceutical composition is administered to the patient twice daily.
[0031] In a further preferred embodiment of the above mentioned oral pharmaceutical composition, the interstitial lung disease with progressive fibrosis (PF-ILD) to be treated is idiopathic pulmonary fibrosis (IPF). In a fourth aspect, the present invention relates to the use of a PDE4B inhibitor of formula III in combination with another oral medicament (as background treatment) comprising a therapeutically effective dose of nintedanib for the manufacture of an oral medicament for treating patients suffering from progressive fibrotic interstitial lung disease (PF-ILD), comprising 18 mg or 9 mg of a PDE4B inhibitor of formula III,
[0032] [ka] Thereby, said oral medicament containing 18 mg or 9 mg of a PDE4B-inhibitor of formula III is administered to the patient twice daily.
[0033] In a preferred embodiment, the present invention relates to the use of a PDE4B inhibitor of formula III in combination with another oral medicament containing 150 mg of nintedanib (as background treatment) for the manufacture of an oral medicament for the treatment of patients suffering from progressive fibrotic interstitial lung disease (PF-ILD), comprising 18 mg or 9 mg of a PDE4B inhibitor of formula III, [ka] Thereby, the oral medication containing a PDE4B-inhibitor of formula III is administered to the patient twice daily.
[0034] In another preferred embodiment, the present invention relates to the use of a PDE4B inhibitor of formula III in combination with another oral medicament containing 100 mg of nintedanib (as background treatment) for the manufacture of an oral medicament for the treatment of patients suffering from progressive fibrotic interstitial lung disease (PF-ILD) comprising 18 mg or 9 mg of a PDE4B inhibitor of formula III, [ka] Thereby, the oral medication containing a PDE4B-inhibitor of formula III is administered to the patient twice daily. In a preferred embodiment, the oral medication referred to above is used for the treatment of idiopathic pulmonary fibrosis (IPF).
[0035] In a fifth aspect, the present invention provides a method for producing a composition comprising the steps of: 18 mg or 9 mg of a PDE4B inhibitor of formula III [ka] A therapeutically effective amount of pirfenidone, and - An oral pharmaceutical composition for treating a patient suffering from progressive fibrotic interstitial lung disease (PF-ILD), optionally comprising one or more pharma- ceutical acceptable carriers or excipients, the oral pharmaceutical composition being administered to the patient twice daily. In a preferred embodiment, the oral pharmaceutical composition referred to above is used for the treatment of idiopathic pulmonary fibrosis (IPF).
[0036] In a sixth aspect, the present invention relates to the use of a PDE4B inhibitor of formula III in combination with another oral medicament (as background treatment) comprising a therapeutically effective dose of pirfenidone for the manufacture of an oral medicament for treating patients suffering from progressive fibrotic interstitial lung disease (PF-ILD), comprising 18 mg or 9 mg of a PDE4B inhibitor of formula III, [ka] Thereby, this oral medication containing a PDE4B-inhibitor of formula III is administered to the patient twice daily.
[0037] As used herein, the interstitial lung disease with progressive fibrosis (PF-ILD) is preferably idiopathic pulmonary fibrosis (IPF). As used herein, the therapeutically effective dose of pirfenidone (as background treatment) in another oral medication is preferably a daily dose of 801 mg to 2403 mg. In a seventh aspect, the present invention provides a method for producing a composition comprising the steps of: - a first pharmaceutical composition or dosage form comprising 18 mg or 9 mg of a PDE4B-inhibitor of formula III; [ka] It may also include one or more pharma- ceutically acceptable carriers and / or excipients, and - a second pharmaceutical composition or dosage form comprising nintedanib at a dose of 100 mg or 150 mg; Also, - A kit for treating a patient suffering from progressive fibrotic interstitial lung disease (PF-ILD), which may comprise one or more pharma- ceutical acceptable carriers and / or excipients, wherein both the first and second pharmaceutical compositions are to be administered twice daily.
[0038] In a preferred embodiment, the above mentioned kit is used for the treatment of idiopathic pulmonary fibrosis (IPF). In a further preferred embodiment of the kit referred to above, the first pharmaceutical composition or dosage form is to be administered simultaneously, simultaneously, sequentially, consecutively, alternatingly or separately with the second pharmaceutical composition or dosage form. In an eighth aspect, the present invention provides a kit for treating a patient suffering from progressive fibrotic interstitial lung disease (PF-ILD), comprising: - a first pharmaceutical composition or dosage form comprising 18 mg or 9 mg of a PDE4B-inhibitor of formula III;
[0039] [ka] It may also include one or more pharma- ceutically acceptable carriers and / or excipients, and - a second pharmaceutical composition or dosage form comprising a therapeutically effective dose of pirfenidone; Also, - kits, which may include one or more pharma- ceutically acceptable carriers and / or excipients; The first therapeutic composition or dosage form should be administered twice daily.
[0040] In a preferred embodiment of the above mentioned kit, the kit is used for the treatment of patients suffering from idiopathic pulmonary fibrosis (IPF). In a further preferred embodiment of the kit referred to above, the first pharmaceutical composition or dosage form is to be administered simultaneously, simultaneously, sequentially, consecutively, alternatingly or separately with the second pharmaceutical composition or dosage form. In further preferred embodiments of the above mentioned kit, the second pharmaceutical composition or dosage form comprises pirfenidone in a dose of 267 mg administered three times a day or in a dose of 534 mg administered three times a day or in a dose of 801 mg administered three times a day. In another preferred embodiment of the above mentioned kit, the second pharmaceutical composition or dosage form comprises pirfenidone in a daily dose of 801 mg to 2403 mg. [Brief description of the drawings]
[0041] [Figure 1] FIG. 1 describes the adjusted mean (SE) for the change from baseline [ml] in forced vital capacity (FVC) in the "non-AF group." In the "non-AF group," after 12 weeks of treatment, the difference in change from baseline in FVC between the "Form. III Comp. group" (= "active agent group") and the "placebo group" was 101.7 ml (MMRM). The curve with data points depicted as filled triangles represents the group that received the "Form. III Comp." (meaning the "active agent group") and the dashed curve with data points depicted as open triangles represents the group that received the "placebo." [Diagram 2]FIG. 1 describes the adjusted mean (SE) for the change from baseline [ml] in forced vital capacity (FVC) in the complete "AF group" ("nintedanib as antifibrotic background medication group" + "pirfenidone as antifibrotic background medication group"). In the complete "AF group", after 12 weeks of treatment, the difference in the change from baseline in FVC between the "Comp. in Form. III" (= "active agent group") and the "placebo group" was 80.4 ml (MMRM). The curve with the data points depicted as filled triangles represents the group that received "Comp. in Form. III" (meaning "active agent group") and the dashed curve with the data points depicted as open triangles represents the group that received "placebo". [Diagram 3] FIG. 1 describes the adjusted mean (SE) for the change from baseline [ml] in forced vital capacity (FVC) in the part of the "AF group" that received nintedanib as antifibrotic background medication ("nintedanib as antifibrotic background medication group"). In the part of the "AF group" that received nintedanib as antifibrotic background medication, after 12 weeks of treatment, the difference in the change from baseline in FVC between the "Comp. of Form. III group" (= "active agent group") and the "placebo group" was 105.43 ml (MMRM). The curve with the data points depicted as filled triangles represents the group that received "Comp. of Form. III" (meaning "active agent group") and the dashed curve with the data points depicted as open triangles represents the group that received "placebo". [Figure 4]FIG. 1 describes the adjusted mean (SE) for the change from baseline [ml] in forced vital capacity (FVC) in the part of the "AF group" that received pirfenidone as antifibrotic background medication ("Pirfenidone as antifibrotic background medication group"). In the part of the "AF group" that received pirfenidone as antifibrotic background medication, after 12 weeks of treatment, the difference in the change from baseline in FVC between the "Comp. of Form. III group" (= "active agent group") and the "placebo group" was 61.30 ml (MMRM). The curve with the data points depicted as filled triangles represents the group that received "Comp. of Form. III" (meaning "active agent group"), and the dashed curve with the data points depicted as open triangles represents the group that received "placebo". [Diagram 5] FIG. 1 describes the adjusted mean (SE) for the change from baseline [ml] in forced vital capacity (FVC) in the "pooled AF background" (= "non-AF group" + complete "AF group"). In the "pooled AF background", after 12 weeks of treatment, the difference in the change from baseline in FVC between the "Comp. in Form. III" (= "active agent group") and the "placebo group" was 88.38 ml (MMRM). The curve with data points depicted as solid circles represents the group that received the "Comp. in Form. III" (meaning the "active agent group") and the dashed curve with data points depicted as open circles represents the group that received the "placebo". [Figure 6] FIG. 1 describes the adjusted mean (SE) change from baseline [ml] in forced vital capacity (FVC) in the complete "AF group" (= "antifibrosis"), the "non-AF group" (= "no antifibrosis") and the "pooled AF background" (= "all patients") at week 12 (MMRM).
[0042] 3. Clinical Trials 3.1 Detailed description of the clinical trial The study was open to adults with idiopathic pulmonary fibrosis (IPF) who were at least 40 years old at the time of recruitment. People taking standard medications for IPF, including anti-fibrotic drugs, continued to take them throughout the study.
[0043] The objective of the study was to find out whether a PDE4 inhibitor of formula III could slow the deterioration of lung function.
[0044] [ka] Participants participated in the study for approximately four months. During this time, participants visited the study site approximately seven times. At the start, participants visited the study site every two weeks. One month after treatment, participants visited the study site every four weeks.
[0045] Participants were divided by chance into two groups ("active group" and "placebo group"). One tablet containing 12 mg of the compound of formula III and one tablet containing 6 mg of the compound of formula III (the "active tablet" is a single dose of 18 mg, see Table 1) were orally administered twice daily (bid) to patients in the first group. One 12 mg placebo tablet and one 6 mg placebo tablet (both containing no active ingredient, see Table 1) were orally administered twice daily (bid) to patients in the second group. The placebo tablet looks like a tablet of the active ingredient (= the compound of formula III).
[0046] [Table 1] The "active agent group" and the "placebo group" were further divided into two different groups regarding background medication: the "AF group" ("antifibrotic background medication group") and the "non-AF group" ("non-antifibrotic background medication group"). Some patients in the "non-AF group" did not receive antifibrotic background medication (approved dose and administration regimen) of nintedanib or pirfenidone during the trial (meaning that a PDE4B inhibitor of formula III at a dose of 18 mg bid (= twice daily) or a placebo at bid (twice daily) was administered alone), and some patients in the "AF group" received antifibrotic background medication of nintedanib or pirfenidone during the trial (meaning that a PDE4B inhibitor of formula III at a dose of 18 mg bid (= twice daily) or a placebo at bid (twice daily) was administered in combination with nintedanib or pirfenidone). The combination of both nintedanib and pirfenidone as background medication was not allowed in the "AF group".
[0047] Participants underwent pulmonary function tests ("forced vital capacity (FVC)") during study visits. Results of changes in pulmonary function tests were compared between the "active agent group" and the "placebo group" (both within the "AF group" and within the "non-AF group"). Physicians also regularly checked the participants' general health.
[0048] The study recruited 147 IPF patients who met the following inclusion criteria: • Patients aged ≥40 years at the time of signing informed consent. Diagnosis: IPF according to the 2018 ATS / ERS / JRS / ALAT guidelines, confirmed by the investigator based on a chest high-resolution computed tomography scan (HRCT) scan taken within 12 months of Visit 1 and a surgical lung biopsy, if available. and Visit 2 if an equivocal HRCT showing IPF can be focally confirmed by (previous) biopsy *Prior to the initial diagnosis, patients were confirmed by central review to have usual interstitial pneumonia (UIP) or a high-probability UIP HRCT pattern consistent with a clinical diagnosis of IPF. • Stable for at least 8 weeks prior to visit 1. The patient: - Must not have participated in treatment with nintedanib or pirfenidone for at least 8 weeks prior to Visit 1 (the combination of nintedanib and pirfenidone is not permitted) or - Stable treatment with nintedanib or pirfenidone for at least 8 weeks prior to Visit 1 * Patients must be enrolled in a plan that remains stable on this background treatment after randomization. [ * Stable treatment is defined as a regimen of pirfenidone or nintedanib that is individually and generally tolerated (the combination of nintedanib and pirfenidone is not permitted)]. Forced vital capacity (FVC) ≥ 45% of normal predicted at visit 1 Pulmonary diffusion capacity for carbon monoxide (DLCO) (corrected for hemoglobin [Hb] [Visit 1]) ≥25% to <80% of predicted normal at Visit 1. Prior to acceptance into the trial, written informed consent was signed and dated in accordance with ICH-GCP and local regulations.
[0049] The following exclusion criteria were applied to the participating IPF patients: - Associated airway obstruction at visit 1 (pre-bronchodilator forced expiratory volume in one second (FEV1) / forced vital capacity (FVC) <0.7). • Other clinically significant pulmonary abnormalities in the opinion of the investigator. Acute IPF exacerbation (as assessed by the investigator) within 4 months prior to screening and / or during the screening period. • Lower respiratory tract infection requiring antibiotics within 4 weeks prior to Visit 1 and / or during the screening period. ●Major surgery (major as assessed by the investigator) performed within 3 months prior to Visit 1 or planned during the course of the trial (will allow placement on the transplant list). • Any active or suspected malignancy or history of malignancy documented within the 5 years prior to Visit 1, except adequately treated basal cell carcinoma of the skin, "under surveillance" prostate cancer, or cervical intraepithelial neoplasia. • Evidence of active infection (chronic or acute) based on clinical or laboratory findings at Visit 1 or Visit 2. • Any suicidal attempt (i.e., actual attempt, aborted attempt, failed attempt, or preparatory actions or behavior) in the past 2 years. ●The patient had confirmed infection with SARS-CoV-2 within the 4 weeks prior to Visit 1 and / or during the screening period. • Further exclusion criteria apply.
[0050] The trial was a randomized, double-blind, placebo-controlled, parallel-group study. During the 12 weeks of the study, lung function of all enrolled IPF patients was monitored by measuring the change from baseline in forced vital capacity (FVC) ("primary outcome measure"). During the 12 weeks of the treatment period and one week after the treatment period (time frame: up to week 13), treatment-emergent adverse events (TEAEs) were monitored in all enrolled IPF patients ("secondary outcome measure").
[0051] 3.2 Phase II Clinical Trial Results: 3.2.1 Total population Of the 147 patients, those who prematurely discontinued the trial medication were 10 / 49 (20.4%) in the "AF group" and 5 / 49 (10.4%) in the "non-AF group," all of whom were in the "active agent group." The most frequent reason for early discontinuation was adverse events, which accounted for 100% (10 / 10 discontinuations) in the “AF group” and 60% (3 / 5 discontinuations) in the “non-AF group” (see Table 2).
[0052] [Table 2]
[0053] Table 3 shows that the time from diagnosis of IPF was longer in the “AF group” (4.33 years) versus the “non-AF group” (2.54 years) and was balanced between the placebo control and active agent arms. [Table 3]
[0054] Table 4 shows that IPF patients in the "AF group" used nintedanib more than pirfenidone as background medication (53.1% nintedanib and 46.9% pirfenidone in the "active group", 68% nintedanib and 32% pirfenidone in the "placebo group"). Furthermore, Table 4 shows that in IPF-patients from the "AF group", the time since diagnosis of IPF was longer (4.6 years in the "active group" and 3.9 years in the "placebo group") than in patients in the "non-AF group" (2.7 years in the "active group" and 2.2 years in the "placebo group").
[0055] [Table 4]
[0056] 3.2.2 Results Concerning the Efficacy of PDE4-Inhibitors of Formula III 3.2.2.1 Results in the "non-AF group" Trimmed mean estimates (mixed model repeated measures, MMRM): The IPF patients in the "non-AF group" received a tablet containing 18 mg of the compound of formula III twice a day (= "active group") or a placebo tablet without active ingredient twice a day (wherein the "placebo tablet" is indistinguishable from the "active tablet" containing 18 mg of the compound of formula III in terms of appearance, smell, taste, etc.). The patients in the "non-AF group" did not receive standard of care background medication to treat IPF during the 12-week study period (meaning no nintedanib background medication and no pirfenidone background medication). Each patient tested underwent pulmonary function tests at regular intervals during each study visit. From the results of these pulmonary function tests, the change (ml) from baseline in FVC at different time points in the study was determined (see Figure 1). The patient's data from pulmonary function tests at different time points within the 12-week study period was analyzed by mixed model repeated measures (MMRM). MMRM is an established method for analyzing longitudinal data, allowing the use of repeated measurement sets of patients in the estimation process (Fitzmaurice et al., “Longitudinal Data Analysis, Chapman & Hall / CRC, New York (2009)).
[0057] The change from baseline in FVC from the start of the study to the 12th week was -95.62 ml in the "placebo group" and +6.10 ml in the "active group", resulting in a difference of 101.72 ml between the "active group" and the "placebo group" in the change from baseline in FVC from the start of the study to the 12th week (see Table 5, Figures 1 and 6). On the other hand, the change from baseline in FVC in the "placebo group" substantially decreased during the 12-week long study period (meaning that in these untreated patients, the IPF disease had substantially progressed), while the change from baseline in FVC in the "active group" (receiving a PDE4-inhibitor of formula III at a dose of 18 mg twice a day) remained stable or even increased slightly during the same 12-week long study period (see Figures 1 and 6). As a result, the PDE4-inhibitor of formula III at a dose of 18 mg twice daily shows excellent therapeutic efficacy in IPF-patients over a 12 week treatment period without the standard of care background medications of nintedanib or pirfenidone.
[0058] [Table 5]
[0059] 3.2.2.2 Results in the "AF group" Trimmed mean estimate (MMRM): IPF patients in the "AF group" received either a tablet containing 18 mg of the compound of formula III twice a day (= "active agent group") or a placebo tablet that looked similar but had no active ingredients twice a day (= "placebo group"). In addition, patients in the "AF group" received standard of care background medications for treating IPF during the 12-week study period (meaning nintedanib background medication at the approved dose / administration regimen or pirfenidone background medication at the approved dose / administration regimen; a combination of both nintedanib and pirfenidone as background medications was not allowed). Each patient tested had pulmonary function tests performed at regular intervals during each study visit. From the results of these pulmonary function tests, the change from baseline (ml) in FVC at different time points in the study was determined (see Figure 2). Patient data from pulmonary function tests at different time points within the 12-week study period was analyzed by mixed model repeated measures (MMRM).
[0060] The change from baseline in FVC from the start of the study to week 12 was -77.7 ml in the "placebo group" and +2.72 ml in the "active group" (see Table 6, Figures 2 and 6), resulting in a difference of 80.42 ml between the "active group" and the "placebo group" in the change from baseline in FVC from the start of the study to week 12. On the other hand, the change from baseline in FVC in the "placebo group" (the "placebo group" in the "AF group" received only antifibrotic background medication, meaning only nintedanib or only pirfenidone) decreased during the 12-week long study period (meaning that in these patients, IPF disease progressed with antifibrotic background medication alone), while the change from baseline in FVC in the "active group" (receiving a PDE4 inhibitor of formula III at a dose of 18 mg twice daily in combination with antifibrotic background medication of nintedanib or pirfenidone) remained stable or even increased slightly during the same 12-week long study period (see Figures 2 and 6). As a result, the PDE4 inhibitor of formula III in a dose of 18 mg twice daily in combination with antifibrotic background medication (nintedanib or pirfenidone) shows greatly improved therapeutic efficacy in IPF-patients over a 12-week treatment period compared to the therapeutic effect in IPF-patients treated with the same antifibrotic background medication alone.
[0061] This change in FVC from baseline to week 12, 80.42 ml in the “AF group,” compared with 101.72 ml in the “non-AF group,” when comparing the “active agent group” and the “placebo group.” However, this is understandable because antifibrotic background drug therapy with nintedanib or pirfenidone should also play a fundamental role in the treatment of the “AF group.”
[0062] [Table 6]
[0063] However, when the results from the "AF group" were analyzed separately according to the type of antifibrotic background medication administered to the patients (meaning separating the "nintedanib background medication group" from the "pirfenidone background medication group" within the "AF group"), a trend towards higher therapeutic efficacy in combination with 18 mg of a PDE4 inhibitor of formula III administered twice daily was observed in the group receiving nintedanib as background medication compared to the group receiving pirfenidone as background medication.
[0064] This trend can be concluded from the data summarized in Table 7: here in the group receiving nintedanib as background medication, an adjusted mean difference of 105.43 ml between the "active" and "placebo" groups in the change from baseline to week 12 was calculated from the trial data, whereas in the group receiving pirfenidone as background medication, an adjusted mean difference of only 61.30 ml between the "active" and "placebo" groups in the change from baseline to week 12 was calculated from the trial data (see Table 7). In cases where no distinction was made between nintedanib or pirfenidone as background medication, an adjusted mean difference between the change from baseline to week 12 between the "active drug group" and the "placebo group" of 80.42 ml was determined, a value that fell within the range (see Table 6 for comparison).
[0065] The progression of change from baseline in FVC over 12 weeks of treatment can be taken from Figure 3 for the "nintedanib as background medication group" and from Figure 4 for the "pirfenidone as background medication group." [Table 7] As a result, data from clinical trials indicate that a combination of 18 mg of a PDE4 inhibitor of formula III administered twice daily and nintedanib (at approved doses and dosing regimens) may have better therapeutic efficacy than a combination of 18 mg of a PDE4 inhibitor of formula III administered twice daily and pirfenidone (at approved doses and dosing regimens).
[0066] 3.2.2.3 Results for "pooled background therapy" ("non-AF group" + "AF group") Trimmed mean estimate (MMRM): The combined results for the "non-AF group" and the "AF group" led to the results shown in Figure 5 or Figure 6 or summarized in Table 8. The change from baseline in FVC in the "placebo group" (with or without antifibrotic background medication, depending on whether the patient was in the "non-AF group" or the "AF group") steadily decreased over the 12-week long study period, whereas the change from baseline in FVC in the "active group" (receiving a PDE4 inhibitor of formula III at a dose of 18 mg twice daily, alone or in combination with nintedanib or pirfenidone antifibrotic background medication, depending on whether the patient was in the "non-AF group" or the "AF group") remained stable or even increased slightly over the same 12-week long study period (see Figures 5 and 6).
[0067] The change in FVC from baseline to week 12 was -4.59 ml in the "active drug group" and -83.79 ml in the "placebo group" when considering all outcomes (meaning the results in the "non-AF group" + "AF group"). The change in FVC from baseline to week 12, comparing the "active drug group" and the "placebo group", when considering all outcomes (meaning the results in the "non-AF group" + "AF group"), was calculated to be 88.38 ml.
[0068] [Table 8]
[0069] 3.2.3 Safety / Tolerability Results of PDE4-Inhibitors of Formula III In the "active agent group", 67% of patients, 64.6% in the "non-AF group", and 73.5% in the "AF group", experienced adverse events (AEs). In the "placebo group", 60% of patients, 52% in the "non-AF group", and 68% in the "AF group", experienced AEs (see Table 9). Of all the tested groups, only 8.8% of patients who experienced AEs led to discontinuation of the trial drug, 7.5% of patients experienced serious adverse events (see Table 10), and two patients (meaning 1.4%) who experienced AEs led to death (both in the "active agent group", one due to Covid-19 pneumonitis and one due to an unconfirmed case of vasculitis).
[0070] [Table 9]
[0071] [Table 10-1] [Table 10-2] The most frequently reported adverse events (AEs) were gastrointestinal disorders, of which diarrhea was the most frequent AE (diarrhea was observed in more than 10% of all patients (see Table 11)).
[0072] In both the "AF group" and "non-AF group", an increased frequency of the adverse event diarrhea was observed in the corresponding "active agent group" (where the compound of formula III was administered alone or in combination with antifibrotic background medication) compared to the respective "placebo group". Three patients from the "active agent group" discontinued treatment due to the AE diarrhea, all of whom were males aged ≥ 65 years from the "AF group" under background treatment with nintedanib. Among the "non-AF" patients, diarrhea was reported approximately twice as frequently (16.7%) in the "active" group as in the corresponding "placebo" group (8%) (see Table 11). Among the "AF" patients, diarrhea was reported approximately twice as frequently (30.6%) in the "active" group as in the corresponding "placebo" group (16.0%) (see Table 11). However, the overall level of diarrhea reported within the "AF group" was still elevated compared to the "non-AF group" (see Table 11, within the "Placebo group", 16% in the "AF group" had diarrhea compared to 8% in the "non-AF group"; within the "Form. III Comp." group, 30.6% in the "AF group" had diarrhea compared to 16.7% in the "non-AF group").
[0073] As a result, the PDE4-inhibitor of formula III administered at a dose of 18 mg twice daily appears to cause an increased frequency of the AE diarrhea, but the antifibrotic background medication, in particular background medication with nintedanib, also appears to contribute significantly to the increased frequency of reported cases of diarrhea in the "AF group" (compared to the "non-AF group"). Nevertheless, all cases of diarrhea reported within the "AF group" and within the "non-AF group" were not serious adverse events (see Table 10).
[0074] The majority of reported diarrhea events were mild, with the exception of two moderate cases (2.1%) and one severe case (1.0%), all of which occurred in men in the active arm of the AF group on background nintedanib therapy. One severe case of diarrhea occurred in a 64-year-old woman in the placebo arm of the AF group on background nintedanib therapy. Overall, the most frequently reported AE leading to discontinuation was diarrhea (n=4), and all of these cases were part of the “AF group” and were on nintedanib background medication. Among the reported cases of diarrhea within all treatment arms, no cases of diarrhea-associated dehydration were observed. No cases of hypokalemia were reported in any treatment arm.
[0075] Apart from gastrointestinal disorders (specifically diarrhea), only single adverse events were reported across all treatment arms without any particular pattern (in the "AF group" and "non-AF group", in the "active agent group" and in the "placebo group") (see Table 11). [Table 11-1] [Table 11-2]
[0076] 3.2.3.2 Results regarding the safety / tolerability of PDE4-inhibitors of formula III within the "AF group" (separated by type of antifibrotic background treatment) Comparing the results regarding the frequency of "gastrointestinal disorders" AE, and in particular the frequency of the AE "diarrhoea", in the complete "AF group" on the one hand (shown in Table 11) and in the part of the "AF group" that received nintedanib as antifibrotic background medication (the "nintedanib background medication group") and in the part of the "AF group" that received pirfenidone as antifibrotic background medication (the "pirfenidone background medication group") (as shown in Table 14), it became evident that the "pirfenidone background medication group" showed a clearly lower frequency of the AE "gastrointestinal disorders": In the complete AF group in the Comp. arm of form III, 36.7% of patients experienced gastrointestinal disorders (see Table 11). In the "nintedanib background medication subgroup" of the "Comp. arm of form III," 46.2% of patients experienced gastrointestinal disorders (see Table 14). Also, In the "Pirfenidone Background Medication Subgroup" in the "Comp. Arm of Form III," only 26.1% of patients experienced gastrointestinal disorders (see Table 14). Comparable results can be found from the "placebo group" of each of the "AF groups": In the placebo arm, 32.0% of patients in the complete AF group experienced gastrointestinal disorders (see Table 11). In the placebo arm, 41.2% of patients in the nintedanib background medication subgroup experienced gastrointestinal disorders (see Table 14). Also, In the "Placebo Arm," only 12.5% of patients in the "Pirfenidone Background Medication Subgroup" experienced gastrointestinal disorders (see Table 14).
[0077] If we analyze the situation of AE “diarrhea” in the “Comp. arm of form. III”, the exact same tendency can be observed: In the "Comp. arm of form III," 30.6% of patients in the complete "AF group" experienced diarrhea (see Table 11). In the "Comp. arm of form III," 46.2% of patients in the "nintedanib background medication subgroup" experienced diarrhea (see Table 14). Also, In the "Comp. arm of form III," only 13.0% of patients in the "pirfenidone background medication subgroup" experienced diarrhea (see Table 14). Also, for each "placebo arm": In the placebo arm, 16.0% of patients in the complete AF group experienced diarrhea (see Table 11). In the placebo arm, 23.5% of patients in the nintedanib background medication subgroup experienced diarrhea (see Table 14). Also, In the "Pirfenidone Background Medications Subgroup" in the "Placebo Arm," exactly 0% of patients experienced diarrhea (see Table 14).
[0078] This trend towards a reduced trend towards GI AEs, specifically diarrhea, in cases where pirfenidone is used as the antifibrotic background medication (compared to nintedanib as the antifibrotic background medication), is also supported by Table 15, which shows the frequency / percentage of adverse events leading to discontinuation of trial medication. From Table 15, it is evident that within the "AF group" in the "active agent arm" ("compound of formula III"), the combination of 18 mg bid compound of formula III with nintedanib as background medication led to: Four (15.4%) cases of discontinuation of trial treatment due to gastrointestinal disorders were reported as AEs. and Three (11.5%) trials were discontinued due to diarrhea.
[0079] On the other hand, the combination of 18 mg bid compound of formula III and pirfenidone as background medication did not lead to any interruption of trial treatment (see Table 15). In all treatment arms (meaning in each "active agent group" and "placebo group") using pirfenidone as background medication, no single case of interruption of trial treatment due to any gastrointestinal AE was recorded (see Table 15). Thus, the combination treatment with 18 mg bid compound of formula III and pirfenidone as background treatment (at the approved dose) may be accompanied by a reduced frequency and severity of the AE gastrointestinal disorders, in particular a reduced frequency and severity of the AE diarrhea, compared with the combination treatment with 18 mg bid compound of formula III and nintedanib as background treatment (at the approved dose).
[0080] [Table 12]
[0081] [Table 13]
[0082] [Table 14-1] [Table 14-2]
[0083] [Table 15]
[0084] 4. Conclusion The results of the "non-AF group" of the clinical trial support the hypothesis that a PDE4 inhibitor of formula III administered at a dose of 18 mg twice a day (bid) without antifibrotic background medication will substantially slow down the decline of FVC in IPF-patients over a 12-week treatment period ("non-AF group": "form. III Comp. (=active agent) group", after 12 weeks the change from baseline in FVC is +6.1 ml; in the respective "placebo group", after 12 weeks the change from baseline in FVC is -95.6 ml (see Table 5, Figure 1)). In the "non-AF group", this resulted in an adjusted mean difference between the change in FVC from baseline to week 12 of 101.72 ml between the "active agent group" and the "placebo group", thus supporting the hypothesis that PDE4-inhibitors of formula III administered to PF-ILD / IPF patients at a dose of 18 mg twice daily, without antifibotic background treatment, show high therapeutic efficacy in the treatment of PF-ILD patients, preferably IPF patients (see Table 5, Figure 1).
[0085] Meanwhile, only one patient (2.1%) in the "active drug group" experienced gastrointestinal disorders leading to discontinuation of the trial, compared to no patients (0%) in the "placebo group" in the "non-AF arm" (see Table 15). Some results of the "AF group with nintedanib as antifibrotic background medication" support the hypothesis that a PDE4 inhibitor of formula III administered at a dose of 18 mg twice a day (bid) in combination with nintedanib as antifibrotic background medication slows down the decline of FVC in IPF-patients during the 12-week treatment period compared to treatment with nintedanib alone ("AF group with nintedanib as background medication": "Comp. (=active agent) group of form. III": after 12 weeks, the change from baseline in FVC is +23.41 ml; in the respective "placebo group": after 12 weeks, the change from baseline in FVC is -82.01 ml (see Table 7, Figure 3)).
[0086] This results in an adjusted mean difference between the change in FVC from baseline to week 12 between the "active agent group" and the "placebo group" in the "AF group receiving nintedanib as antifibrotic background medication" of 105.43 ml (see Table 7, Figure 3). This supports the hypothesis that a combination of 18 mg of a PDE4 inhibitor of formula III administered twice daily and nintedanib (administered at approved doses and dosing regimens) may elicit exceptionally high therapeutic efficacy. On the other hand, compared to no patients (0%) in the "placebo group" of the "AF arm using nintedanib as antifibrotic background medication," 4 patients (15.4%) in the "active agent group" experienced gastrointestinal disorders as an AE leading to discontinuation of trial treatment, and 3 of these 4 patients experienced diarrhea as an AE leading to discontinuation of trial treatment (see Table 15).
[0087] The results of the "AF group receiving pirfenidone as antifibrotic background medication" show that 18 mg of a PDE4 inhibitor of formula III administered twice a day (bid) in combination with pirfenidone as antifibrotic background medication slows down FVC decline in IPF-patients during the 12-week treatment period compared to treatment with pirfenidone alone ("AF group using pirfenidone as background medication": The hypothesis is supported that in the "form. III Comp. (=active agent) group", after 12 weeks the change from baseline in FVC is -18.67 ml; in the respective "placebo group", after 12 weeks the change from baseline in FVC is -80.06 ml (see Table 7, Figure 4). This results in an adjusted mean difference of 61.30 ml between the change in FVC from baseline to week 12 between the "active agent group" and the "placebo group" in the "AF group receiving pirfenidone as antifibrotic background medication" (see Table 7, Figure 4).
[0088] On the other hand, not a single patient in the "AF arm with pirfenidone as antifibrotic background medication," either in the "active agent group" or the "placebo group," experienced gastrointestinal disorders that led to discontinuation of the trial (see Table 15). At the same time, administration of 18 mg of the PDE4 inhibitor of formula III twice daily (bid) increased the frequency of the adverse event "gastrointestinal disorders" in all treatment arms (in the "non-AF" and "AF" groups), specifically the frequency of the AE "diarrhea." However, among the "AF group", the frequency and severity of reported adverse events gastrointestinal disorders, and more specifically the frequency and severity of reported adverse events diarrhea, were strongly dependent on the type of antifibrotic background medication used. In IPF-patients who received pirfenidone as antifibrotic background medication, adverse events gastrointestinal disorders, and more specifically the adverse event diarrhea, were recorded less frequently and led to discontinuation of the trial treatment less frequently than in IPF-patients who received nintedanib as antifibrotic background treatment (see Tables 14 and 15).
[0089] In IPF-patients who received nintedanib as antifibrotic background medication, adverse events of gastrointestinal disorders, in particular adverse events of diarrhea, were recorded frequently, which in some cases led to the discontinuation of the trial treatment (see Tables 14 and 15). However, IPF-patients who received nintedanib as antifibrotic background medication showed better therapeutic efficacy than IPF-patients who received pirfenidone as antifibrotic background treatment. As a result, the results of the presented Phase II trial in the "AF group with nintedanib as antifibrotic background treatment" support the hypothesis that a PDE4-inhibitor of formula III at a dose of 18 mg twice daily in combination with nintedanib background treatment (at the dose and administration regimen approved for nintedanib, preferably at 150 mg bid or 100 mg bid) may result in a superior therapeutic efficacy combined with a tolerable and safety profile (leading to acceptable compliance). The combination of nintedanib and a PDE4-inhibitor of formula III at a dose of 18 mg twice daily may therefore be suitable in particular for PF-ILD / IPF-patients who do not have a tendency or predisposition to gastrointestinal disorders, in particular diarrhea, or who have not previously experienced problems with gastrointestinal disorders, in particular diarrhea, in their PF-ILD / IPF treatment history.
[0090] As a result, the results of the presented Phase II trial in the "AF group with pirfenidone as antifibrotic background treatment" support the hypothesis that a PDE4-inhibitor of formula III at a dose of 18 mg twice daily in combination with pirfenidone background treatment (at doses and administration regimens approved for pirfenidone, preferably at doses and administration regimens resulting in a daily dose of 801 mg to 2403 mg) may cause a satisfactory therapeutic efficacy (leading to good patient compliance) combined with a good tolerability and safety profile. The combination of pirfenidone and a PDE4-inhibitor of formula III at a dose of 18 mg twice daily may therefore be suitable in particular for PF-ILD / IPF-patients who have a predisposition or tendency to gastrointestinal disorders, in particular diarrhea, or who have previously experienced problems with gastrointestinal disorders, in particular diarrhea, in their PF-ILD / IPF treatment history.
Claims
1. Essentially, 18 mg of a PDE4B-inhibitor of formula III; 【Chemistry 1】 1. An oral pharmaceutical composition for use in treating a patient suffering from one or more progressive fibrotic interstitial lung diseases (PF-ILDs), optionally comprising one or more pharmacokinetic or kinetically specific pulmonary fibrosis (PFI)-ILDs, the composition being administered to the patient twice daily.
2. The oral pharmaceutical composition of claim 1, wherein the one or more progressive fibrotic interstitial lung diseases (PF-ILDs) is idiopathic pulmonary fibrosis (IPF).
3. 3. The oral pharmaceutical composition according to claim 1, which is a film-coated tablet.
4. 1. Use of a PDE4B-inhibitor of formula III for the manufacture of an oral pharmaceutical composition for treating a patient suffering from progressive fibrotic interstitial lung disease (PF-ILD), consisting essentially of 18 mg of a PDE4B-inhibitor of formula III and, optionally, one or more pharma- ceutically acceptable carriers or excipients, 【Chemistry 2】 The oral pharmaceutical composition is administered to a patient twice daily.
5. Use of a PDE4B-inhibitor of formula III according to claim 4, wherein the interstitial lung disease with progressive fibrosis (PF-ILD) is idiopathic pulmonary fibrosis (IPF).
6. Use of a PDE4B-inhibitor of formula III according to at least one of claims 4 or 5, wherein the oral pharmaceutical composition is a film-coated tablet.
7. containing a PDE4B-inhibitor of formula III as the sole active agent at a dose of 18 mg, 【Chemistry 3】 1. An oral pharmaceutical composition for treating a patient suffering from progressive fibrotic interstitial lung disease (PF-ILD), which may comprise one or more pharma- ceutical carriers or excipients, the oral pharmaceutical composition being administered to the patient twice daily.
8. The oral pharmaceutical composition according to claim 7, wherein the progressive fibrotic interstitial lung disease (PF-ILD) is idiopathic pulmonary fibrosis (IPF).
9. 9. The oral pharmaceutical composition according to at least one of claims 7 or 8, which is a film-coated tablet.
10. Use of a PDE4B-inhibitor of formula III for the manufacture of an oral pharmaceutical composition for treating patients suffering from progressive fibrotic interstitial lung disease (PF-ILD), comprising a PDE4B-inhibitor of formula III as the only active agent in a dose of 18 mg, and optionally one or more pharma- ceutical acceptable carriers or excipients, 【Chemistry 4】 The oral pharmaceutical composition is administered to a patient twice daily.
11. Use of a PDE4B-inhibitor of formula III according to claim 10, wherein the interstitial lung disease with progressive fibrosis (PF-ILD) is idiopathic pulmonary fibrosis (IPF).
12. Use of a PDE4B-inhibitor of formula III according to at least one of claims 10 or 11, wherein the oral pharmaceutical composition is a film-coated tablet.
13. A method of treating a patient suffering from progressive fibrotic interstitial lung disease (PF-ILD), comprising administering to said patient a PDE4B-inhibitor of formula III as the sole active agent in a dose of 18 mg, 【Chemistry 5】 A method comprising administering to a patient twice daily an oral pharmaceutical composition, which may include one or more pharma- ceutically acceptable carriers or excipients.
14. The method of claim 13, wherein the progressive fibrotic interstitial lung disease (PF-ILD) is idiopathic pulmonary fibrosis (IPF).
15. The method according to at least one of claims 13 or 14, wherein the oral pharmaceutical composition is a film-coated tablet.
16. 1. A method of treating a patient suffering from progressive fibrotic interstitial lung disease (PF-ILD), comprising administering to the patient 18 mg of a PDE4B-inhibitor of formula III, 【Chemistry 6】 Optionally, the method comprises administering to the patient twice daily an oral pharmaceutical composition comprising one or more pharma- ceutically acceptable carriers or excipients.
17. The method of claim 16, wherein the progressive fibrotic interstitial lung disease (PF-ILD) is idiopathic pulmonary fibrosis (IPF).
18. The method according to at least one of claims 16 or 17, wherein the oral pharmaceutical composition is a film-coated tablet.
Citation Information
Patent Citations
Novel piperidino-dihydrothienopyrimidine sulfoxide and its use for the treatment of COPD and asthma
JP2014524452A
Novel combinations of active agents for the treatment of progressive fibrosing interstitial lung disease (PF-ILD)
JP2021500362A
